Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
회사 코드IXHL
회사 이름Incannex Healthcare Inc
상장일Mar 18, 2022
설립일2023
CEOMr. Joel Latham
직원 수9
유형Ordinary Share
회계 연도 종료Mar 18
주소8 Century Circuit
도시
증권 거래소NASDAQ Global Market Consolidated
국가Australia
우편 번호2153
전화61409840786
웹사이트
회사 코드IXHL
상장일Mar 18, 2022
설립일2023
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음